Human Longevity Launches $599 Whole Genome Sequencing with AI Insights
Human Longevity, Inc. announced in a press release the launch of its Clinical Grade Whole Genome Sequencing Report, available for $599. The new service combines genomic sequencing with AI supported analysis to help identify inherited disease risks, carrier status, pharmacogenomic factors, and longevity related traits.
The offering honors the legacy of Dr. J. Craig Venter, whose work on decoding the first human genome laid the foundation for modern genomics. Human Longevity stated that over the past decade it has invested more than $600 million in building a longitudinal health dataset covering more than 10,000 individuals. This data has been used to train proprietary AI models focused on chronic diseases such as cardiovascular disease, cancer, and dementia.
The company said the new report aims to make clinical grade genome sequencing broadly accessible to the public. The service is available nationwide through Human Longevity’s website.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Nov 13 Bracco and Avicenna.AI win FDA clearance for AI that flags brain aneurysms on CT scans Nov 13 Zus Health raises $33 million to build the data layer for healthcare AI Nov 13 Google DeepMind releases AlphaGenome 2 to predict DNA variant effects in specific cell types Nov 13 Taiwan hospital accelerator T+ MedIC names AI ECG and CT screening tools as first winners Nov 13 Sheinbaum meets OpenAI president Greg Brockman on AI in Mexican healthcareLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Illumina Launches BioInsight Platform for Genomic Research
Ultima Genomics to Sequence 80,000 Samples for UK Biobank Immune Study
Illumina Adds Three Research Tools to BioInsight Platform
SOPHiA GENETICS revenue rises 25% to $24.3 million
INmune Bio and QCi Apply Quantum Computing to XPro Research
Daily AI Brief: the AI news that matters, in your inbox.